Tissue Transplantation



Blood Group Acute Rejection Chronic Rejection Acute Cellular Rejection Human Leukocyte Antigen Typing 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Abt P, Shaked A. 2003. The allograft immune response. Graft. 6:71–79.CrossRefGoogle Scholar
  2. Alegre ML, Najafian N. 2006. Costimulatory molecules as targets for the induction of transplantation tolerance. Curr Mol Med. 6:843–857.PubMedCrossRefGoogle Scholar
  3. Antin JH, Ferrara JL. 1992. Cytokine dysregulation and acute graft vs host disease. Blood. 80:2964–2968.PubMedGoogle Scholar
  4. Arkelov A, Lakkis FG. 2000. The alloimmune response and effector mechanisms of allograft rejection. Semin Nephrol. 20:95–102.Google Scholar
  5. Azuma H, Tilney NL. 1995. Immune and nonimmune mechanisms of chronic rejection of kidney allografts. J Heat Lung Transplant. 14:S136–S142.Google Scholar
  6. Bellgrau D, Gold D, Selawry H, Moore J, et al. 1995. A role for CD95 ligand in preventing graft rejection. Nature. 377:630–632.PubMedCrossRefGoogle Scholar
  7. Benichou G, Fedoseyeva EV. 1996. The contribution of peptides to T cell allorecognition and allograft rejection. Int Rev Immunol. 13:231–243.PubMedCrossRefGoogle Scholar
  8. Benjamin LC, Allan JS, Madsen JC. 2002. Cytokines in immunity and allograft rejection. Crit Rev Immunol. 22:269–279.PubMedGoogle Scholar
  9. Betkowski AS, Graff R, Chen JJ, Hauptman PJ. 2002. Panel- reactive antibody screening practices prior to heart transplantation. J Heart Lung Transplant. 21:644–650.PubMedCrossRefGoogle Scholar
  10. Billingham RE. 1966. The biology of graft-versus-host reactions. Harvey Lect. 67:21–78.Google Scholar
  11. Bishop DK, Shelby J, Eichwald EJ. 1992. Mobilization of T lymphocytes following cardiac transplantation. Evidence that CD4- positive cells are required for cytotoxic T lymphocyte activation, inflammatory endothelial development, graft infiltration and acute allograft rejection. Transplantation. 53:849–857.PubMedCrossRefGoogle Scholar
  12. Bishop DK, Li W, Chan SY, Ensley RD, et al. 1994. Helper T lymphocytes unresponsiveness to cardiac allografts following transient depletion of CD4-positive cells. Implications for cellular and humoral responses. Transplantation. 58:576–584.PubMedCrossRefGoogle Scholar
  13. Brent L. 1997. History of Transplantation Immunology. Academic Press, San Diego, CA.Google Scholar
  14. Broelsch CE, Burdelski M, Rogiers X, Gundlach M, et al. 1994. Living donor for liver transplantation. Hepatology. 20:49S–55S.PubMedGoogle Scholar
  15. Bromberg JS, Murphy B. 2001. Routes to allograft survival. J Clin Inv. 107:797–798.CrossRefGoogle Scholar
  16. Brook NR, Nicholson ML. 2003. Kidney transplantation from non heart-beating donors. Surgeon. 1:311–322.PubMedCrossRefGoogle Scholar
  17. Bucin D. 1988. Blood transfusion in renal transplantation – The induction of tolerance by incompatibility for class I antigen. Med Hypothesis. 27:19–27.CrossRefGoogle Scholar
  18. Chalasani G, Li Q, Konieczny BT, Smith-Diggs L, et al. 2004. The allograft defines the type of rejection (acute vs chronic) in the face of an established effector immune response. J Immunol. 172:7813–7820.PubMedGoogle Scholar
  19. Codarri L, Vallotton L, Ciuffreda D, Venetz JP, et al. 2007. Expansion and tissue infiltration of an allospecific CD4+CD25+CD45RO+IL-7R (alpha) high cell population in solid organ transplant recipients. J Exp Med. 204:1533–1541.PubMedCrossRefGoogle Scholar
  20. Cooper DK. 1969. Transplantation of the heart and both lungs. I. Historical review. Thorax. 24:383–390.PubMedCrossRefGoogle Scholar
  21. Doyle AM, Lechler RI, Turka LA. 2004. Organ transplantation: Half-way through the first century. J Am Soc Nephrol. 15:2965–2971.PubMedCrossRefGoogle Scholar
  22. Dreger P, Kloss M, Petersen B, Haferlach T, et al. 1995. -Autologous progenitor cell transplantation: Prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood. 86:3970–3978.PubMedGoogle Scholar
  23. El-Asady RS, Rongwen Y, Hadley GA. 2003. The role of CD103 ([alpha]E[beta] 7 integrin) and other adhesion molecules in lymphocyte migration to organ allografts: Mechanisms of rejection. Curr Opin Organ Transplant. 8:1–6.CrossRefGoogle Scholar
  24. Ferrara JL, Deeg HJ. 1991. Graft-versus-host disease. NEJM. 324:667–674.PubMedCrossRefGoogle Scholar
  25. Ferrara JLM, Cooke KR, Pan L, Krenger W. 1996. The immunopathophysiology of acute graft-versus-host-disease. Stem cells. 14:473–489.PubMedCrossRefGoogle Scholar
  26. Field EH, Matesic D, Rigby S, Fehr T, et al. 2001. CD4+CD25+ regulatory cells in acquired MHC tolerance. Immunol Rev. 182:99–112.PubMedCrossRefGoogle Scholar
  27. Flye MW (Ed.). 1989. Principles of Organ Transplantation. W. B. Saunders, Philadelphia, PA.Google Scholar
  28. Galili U. 1993. Interaction of the natural anti-Gal antibody with α-galactosyl epitopes: A major obstacle of xenotransplantation in humans. Immunol Today. 14:480–482.PubMedCrossRefGoogle Scholar
  29. Game DS, Lechler RI. 2002. Pathways of allorecognition: Implications for transplantation tolerance. Transpl Immunol. 10:101–108.PubMedCrossRefGoogle Scholar
  30. Gebel HM, Bray RA. 2000. Sensitization and sensitivity: Defining the unsensitized patients. Transplantation. 69:1370–1374.PubMedCrossRefGoogle Scholar
  31. Goulmy E, Schipper R, Pool J, Blokland E, et al. 1996. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host-disease after bone marrow transplantation. NEJM. 334:281–285.PubMedCrossRefGoogle Scholar
  32. Griepp RB, Ergin MA. 1984. The history of experimental heart transplantation. J Heart Transplant. 3:145–145.Google Scholar
  33. Griffith BP, Hardesty RL, Trento A, Bahnson HT. 1985. Asynchronous rejection of heart and lungs following cardiopulmonary transplantation. Ann Thorac Surg. 40:488–493.PubMedCrossRefGoogle Scholar
  34. Griffith TS, Brunner T, Fletcher SM, Green DR, et al. 1995. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 270:11889–1192.CrossRefGoogle Scholar
  35. Hakim NS. 2003. Recent developments and future prospects in pancreatic transplantation. Exp Clin Transplant. 1:26–34.PubMedGoogle Scholar
  36. Hall B, Jelbart ME, Gurley KE, Dorsch SE. 1990. Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine. III. Further characterization of CD4+ suppressor cell and its mechanisms of action. J Exp Med. 171:141–157.PubMedCrossRefGoogle Scholar
  37. Hall BM, Chen J, Robinson C, Xy H, et al. 2002. Therapy with mab to CD25 blocks function of CD4+CD25+ T regulatory cells which maintain transplantation tolerance. Nephrology. 7:A111–A111.Google Scholar
  38. Hayry P, Isoniemi H, Yilmaz A, Mennander K, et al. 1993. Chronic allograft rejection. Immunol Rev. 134:33–81.PubMedCrossRefGoogle Scholar
  39. Hayry P. 1996. Pathophysiology of chronic rejection. Trans Proc. 28:7–10.Google Scholar
  40. Kahan BD. 1991. Transplantation timeline. Mankind’s three millennia-one maverick’s three decades in the struggle against biochemical individuality. Transplantation. 51:1–21.PubMedCrossRefGoogle Scholar
  41. Kang SM, Tang Q, Bluestone JA. 2007. CD4+CD25+ regulatory T cells in transplantation: Progress, challenges and prospects. Am J Transplant. 7:1457–1463.PubMedCrossRefGoogle Scholar
  42. Kaufman DB, A. 2006. Pancreas transplantation. Koffron www.emedicine.com/med/topic 2605.htm.
  43. Kerman RH, Orosz CG, Lorber MI. 1997. Clinical relevance of anti-HLA antibodies pre and post transplant. Am J Med Sci. 313:275–278.PubMedCrossRefGoogle Scholar
  44. Kitchens WH, Uehara S, Chase CM, Coluin RB, et al. 2006. The changing role of natural killer cells in solid organ rejection and tolerance. Transplantation. 81:811–817.PubMedCrossRefGoogle Scholar
  45. Klein J. 1986. Natural History of the Major Histocompatibility Complex. Wiley, New York.Google Scholar
  46. Krensky AM. 2004. Immunologic tolerance. Ped Nephrol. 16:675–679.CrossRefGoogle Scholar
  47. Krensky AM, Clayberger C. 2004. Prospects for induction of tolerance in renal transplantation. Ped Nephrol. 8:772–779.CrossRefGoogle Scholar
  48. Krieger NR, Yin DP, Fathman CG. 1996. CD4+ but not CD8+ cells are essential for allorejection. J Exp Med. 184:2013–2018.PubMedCrossRefGoogle Scholar
  49. LaRosa DF, Rahman AH, Turka LA. 2007. The innate immune system in allograft rejection and tolerance. J Immunol. 178:7503–7509.PubMedGoogle Scholar
  50. Lattmann T, Hein M, HOrber S, Ortmann J, et al. 2005. Activation of pro-inflammatory and anti-inflammatory cytokines in host organs during chronic allograft rejection: Role of endothelin receptor signaling. Am J Transplant. 5:1042–1049.PubMedCrossRefGoogle Scholar
  51. Lau CL, Palmer SM, Posther KE, Howell DN, et al. 2000. Influence of panel-reactive antibodies on post transplant outcomes in lung transplant recipients. Ann Thorac Surg. 69:1520–1524.PubMedCrossRefGoogle Scholar
  52. Lau HT, Yu M, Fontana A, Stoeckert CJ. 1996. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science. 273:109–112.PubMedCrossRefGoogle Scholar
  53. Majno G. 1975. The Healing Hand. Man and Wound in the Ancient World. Harvard University Press, Cambridge, MA.Google Scholar
  54. Mancini MC. 2006. Heart-lung transplantation. www.emedicine.com/med/topic2063.htm.
  55. Mancini MC, Gangahar DM. 2006. Heart transplantation. www.emedicine.com/med/topic 3187.htm.
  56. Mandanas RA. 2006. Graft vs. host disease. www.emedicine.com/medtopic926.htm.
  57. Manzarbeitia C. 2006. Liver transplantation. www.emedicine.com/med/topic3510.htm.
  58. Matthews LG. 1968. S.S. Cosmas and Damian – Patron Saints of medicine and pharmacy. Their cult in England. Med Hist. 12:281–288.Google Scholar
  59. Medawar PB. 1986. Memoir of a Thinking Radish. Oxford University Press, Oxford.Google Scholar
  60. Merrill JP, Murray JE, Harrison JH, Guild WR. 1984. Landmark article Jan. 28, 1956. Successful homotransplantation of the human kidney between identical twins. JAMA. 251:2566–2571.PubMedCrossRefGoogle Scholar
  61. Morris PJ. 2004. Transplantation – A medical miracle of the 20th century. NEJM. 351:2678–2680.PubMedCrossRefGoogle Scholar
  62. Murphy B, Krensky AM. 1999. HLA-derived peptides as novel immunomodulatory therapeutics. J Am Soc Nephrol. 10:1346–1355.PubMedGoogle Scholar
  63. Norman DJ. 1998. Expected clinical outcomes/risk factors. In: Norman DJ, Suke WN, Thorofare NJ, Eds. Primer on Transplantation, Am. Soc. Transplant Physicians, Thorofare, NJ,pp. 245–250.Google Scholar
  64. Paul LC. 1995. Immunobiology of chronic renal transplant rejection. Blood Purif. 13:206–218.PubMedCrossRefGoogle Scholar
  65. Petersdorf EW, HansenJA, Martin PJ, Woolfrey A, et al. 2001. Major-histocompatibility-complex class I alleles and antigens in hematopoietic cell transplantation. NEJM. 345:1794–1800.Google Scholar
  66. Philip T, Gugliemli C, Hagenbeek A, Somers R, et al. 1995. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. NEJM. 333:1540–1545.PubMedCrossRefGoogle Scholar
  67. Pinderski LJ, Kirklin JK, McGiffin D, Brown R, et al. 2005. Multi-organ transplantation: Is there a protective effect against acute and chronic rejection? J Heart Lung Transplant. 24:1828–1833.PubMedCrossRefGoogle Scholar
  68. Prescilla RP, Mattoo TK. 2006. Immunology of transplant rejection. www.emedicine.com/ped/ topic2841.htm.
  69. Rana RE, Arora BS. 2002. History of plastic surgery in India. J Postgrad Med. 48:76–78.PubMedGoogle Scholar
  70. Reitz BA, Wallwork JL, Hunt SA, Pennock JL, et al. 1982. Heart-lunch transplantation: Successful therapy for patients with pulmonary vascular disease. NEJM. 306:557–564.PubMedCrossRefGoogle Scholar
  71. Rocha PN, Plumb TJ, Crowley SD, Coffman TM. 2003. Effector mechanisms in transplant rejection. Immunol Rev. 196:51–64.PubMedCrossRefGoogle Scholar
  72. Roopenian D, Choi EY, Brown A. 2002. The immunogenomics of minor histocompatibility antigens. Immunol Rev. 190:86–94.PubMedCrossRefGoogle Scholar
  73. Rosenberg AS, Singer A. 1992. Cellular basis of skin allograft rejection: An in vivo model of immune-mediated tissue destruction. Ann Rev Immunol. 10:333–358.CrossRefGoogle Scholar
  74. Rossini AA, Greiner DL, Mordes JP. 1999. Induction of immunologic tolerance for transplantation. Physiol Rev. 79:99–41.PubMedGoogle Scholar
  75. Roush W. 1995. Xenotransplantation. New ways to avoid organ rejection and buoy hopes. Science. 270:234–235.PubMedCrossRefGoogle Scholar
  76. Rubinstein P. 2001. HLA matching for bone marrow transplantation – How much is enough? NEJM. 345:1842–1844.PubMedCrossRefGoogle Scholar
  77. Ruiz P, Sarwar S, Suterwala MS. 2006. Graft versus host disease. www.emedicinecom/ped/topic 893.htm.
  78. Sablinski T, Sayegh MH, Hancock WW, Kut JP, et al. 1991. Differential role of CD4+ cells in the sensitization and effector phases of accelerated graft rejection. Transplantation. 51:226–231.PubMedCrossRefGoogle Scholar
  79. Sade RM. 2005. Transplantation at 100 years: Alexis Carrel, pioneer surgeon. Ann Thorac Surg. 80:2415–2418.PubMedCrossRefGoogle Scholar
  80. Sakaguchi S. 2006. Regulatory T cells: Meden again. Immunol Rev. 212:1–5.Google Scholar
  81. Sakaguchi S, Ono M, Setoguchi R, Yagi H, et al. 2006. Foxp3+CD25+Cd4+ natural regulatory T cells in dominant self tolerance and autoimmune disease. Immunol Rev. 212:8–27.PubMedCrossRefGoogle Scholar
  82. Salvalaggio PRO, Camirand G, Ariyan CD, Deng S, et al. 2006. Antigen exposure during enhanced CTLA-4 expression promotes allograft tolerance in vivo. J Immunol. 176:2292–2298.PubMedGoogle Scholar
  83. Sanfilippo F. 1998. Transplantation tolerance – The search continues. NEJM. 339:1700–1702.PubMedCrossRefGoogle Scholar
  84. Sayegh MH, Carpenter CB. 1996. Role of indirect allorecognition in allograft rejection. Int Rev Immunol. 13:221–229.PubMedCrossRefGoogle Scholar
  85. Sayegh MH, Turka LA. 1998. The role of T cell costimulatory activation pathways in transplant rejection. NEJM. 338:1813–1821.PubMedCrossRefGoogle Scholar
  86. Sayegh MH, Carpenter CB. 2004. Transplantation 50 years later – Progress, challenges and promises. NEJM. 351:2761–2766.PubMedCrossRefGoogle Scholar
  87. Scheinfeld NS, Kuechle MK. 2007. Graft versus host disease. www.emedicine.com/derm/ toic478.htm.
  88. Shapiro AMJ, Lakey JRT, Ryan EA. 2000. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. NEJM. 343:230–238.PubMedCrossRefGoogle Scholar
  89. Sho M, Kishimoto K, Harada H, Livak M, et al. 2005. Requirements for induction and maintenance of peripheral tolerance in stringent allograft models. Proc Nat Acad Sci. 102:13230–13235.Google Scholar
  90. Silverstein AM. 1988. A History of Immunology. Academic Press, San Diego, CA.Google Scholar
  91. Socie G, Mary JY, Lemann M. 2004. Prognostic value of apoptotic cells and infiltrating neutrophils in graft-versus-host disease of the gastrointestinal tract in humans: TNF and Fas expression. Blood. 103:50–57.PubMedCrossRefGoogle Scholar
  92. Spierings E, Vermeulen CJ, Vogt MH, Doerner LE, et al. 2003. Identification of HLA class II restricted H-Y-specific T-helper epitope evoking CD4+ T-helper cells in H-Y-mismatched transplantation. Lancet. 362:610–615.PubMedCrossRefGoogle Scholar
  93. Strom TB. 2004. Is transplantation tolerable? J Clin Inv. 113:1681–1683.Google Scholar
  94. Sullivan KM. 1999. Graft-versus-host disease. In: Thomas ED, Ed. Hematopoietic Cell Transplantation. 2 nd Ed. Blackwell Science, Boston, MA.Google Scholar
  95. Sykes M. 1996. Immunobiology of transplantation. FASEB J. 10:721–730.PubMedGoogle Scholar
  96. Tambur AR, Pamboukian SV, Costanzo MR, Herrera ND, et al. 2005. The presence of HLA-directed antibodies after heart transplantation is associated with poor allograft outcome. Transplantation. 80:1019–1025.PubMedCrossRefGoogle Scholar
  97. Terasaki PE. (Ed.). 1991. A History of Transplantation: Thirty-Five Recollections. UCLA Tissue Typing Laboratory Press, Los Angeles, CA.Google Scholar
  98. Thomas ED, Lochte HL Jr., Lu WC, Ferrebee JW. 1957. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. NEJM. 257:491–496.PubMedCrossRefGoogle Scholar
  99. Tilney NL. 2000. Transplantation and its biology: From fantasy to routine. J Appl Physiol. 89:1681–1689.PubMedGoogle Scholar
  100. Valujskikh A, Lakkis FG. 2003. In remembrance of things past: Memory T cells and transplant rejection. Immunol Rev. 196:65–74.PubMedCrossRefGoogle Scholar
  101. Valujskikh A. 2006. The challenge of inhibiting alloreactive T-cell memory. Am J Transplant. 6:647–651.PubMedCrossRefGoogle Scholar
  102. Van Buskirk AM, Pidwell DJ, Adam PW, Orosz CG. 1997. Transplantation immunology. JAMA. 278:1993–1999.CrossRefGoogle Scholar
  103. Van Twuyver E, Mooijaart RJ, tenBerge IJ, Van der Horst AR, et al. 1991. Pretransplantation blood transfusion revisited. NEJM. 325:1210–1213.PubMedCrossRefGoogle Scholar
  104. Zhang Q, Chen Y, Fairchild RL, Heeger PS, et al. 2006. Lymphoid sequestration of alloreactive memory CD4 T cells promotes cardiac allograft survival. J Immunol. 176:770–777.PubMedGoogle Scholar
  105. Zheng XX, Markees TG, Hancock WW, Li Y, et al. 1999. CTLA4 signals are required to optimally induce allograft tolerance with combined donor specific transfusion and anti-CD154 monoclonal antibody treatment. J Immunol. 162:4983–4990.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  1. 1.Creighton University Medical CenterOmahaUSA

Personalised recommendations